On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) to Release Early Efficacy Data from Combination Study at AACR Annual Meeting

BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer Combination study pairing KEYTRUDA with Bria-IMT is ongoing, with initial efficacy data for the first six patients to be released at AACR Annual Meeting BriaCell has closed the first tranche of a previously announced non-brokered private placement, … Continue reading “BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) to Release Early Efficacy Data from Combination Study at AACR Annual Meeting”

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Closes First Tranche of Private Placement; Plans to Release Early Efficacy Data of Lead Candidate in Combination Study

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced that it has closed the first tranche of a non-brokered private placement of up to 20,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of up to approximately C$2,000,000. According to the … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Closes First Tranche of Private Placement; Plans to Release Early Efficacy Data of Lead Candidate in Combination Study”

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Announces Changes to Board of Directors and a Private Placement Offering

Dr. Rebecca Taub, M.D. and Vaughn C. Embro-Pantalony will be joining the BriaCell board of directors Both additions have extensive experience in the biopharma industry, bringing expert knowledge in the field of clinical oncology Company recently announced a private placement offering that will generate proceeds for the phase IIa combination clinical trial of Bria-IMT with … Continue reading “BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Announces Changes to Board of Directors and a Private Placement Offering”

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Announces $2M Non-Brokered Private Placement Offering

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, on Wednesday announced its intention to complete a non-brokered private placement of up to 20,000,000 common shares of the company at a price of C$0.10 each for gross proceeds of up to roughly C$2,000,000. The size of the private placement … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Announces $2M Non-Brokered Private Placement Offering”

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Achieves Important Milestones in Fight against Advanced Breast Cancer

New, frozen formulation of ready-to-inject Bria-IMT increases potency, simplifies logistics and is expected to reduce cost-per-dose BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer Founder and Director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit in Paris … Continue reading “BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Achieves Important Milestones in Fight against Advanced Breast Cancer”

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Appoints BioPharma Industry Experts to Board of Directors

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced the appointment of Dr. Rebecca Taub, M.D., and Vaughn C. Embro-Pantalony to its board of directors. Dr. Saeid Babaei, Rahoul Sharan and Martin Schmieg have resigned from BriaCell’s board of directors, effective immediately. Since 2016, Taub … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Appoints BioPharma Industry Experts to Board of Directors”

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Secures Investment to Back Clinical Research

Immuno-oncology-focused biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) recently secured support for its novel immunotherapy clinical research in the form of an equity investment of C$500,000 by the company’s recently appointed director, Jamieson Bondarenko (http://nnw.fm/dW4iF). A recent article includes a comment from Bondarenko regarding the investment, where he states, “The importance of accelerating this … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Secures Investment to Back Clinical Research”

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Switches to Frozen Immunotherapy Formula to Boost Potency and Facilitate Transport

The company has announced an increase in the potency of its lead immunotherapy candidate, Bria-IMT, through cryopreservation The frozen formula simplifies logistics and makes it possible for the immunotherapy to reach patients across long distances without a compromise in the safety or efficiency of the treatment The same cryopreservation approach will be utilized in the … Continue reading “BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Switches to Frozen Immunotherapy Formula to Boost Potency and Facilitate Transport”

NetworkNewsAudio – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Interview

About BriaCell BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body’s own immune system in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more … Continue reading “NetworkNewsAudio – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Interview”

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Working to Fill Vital Need for Effective, Lasting Breast Cancer Treatments

Through its advancement of Bria-IMT and Bria-OTS, BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) is developing cutting-edge treatments to address cancer patient needs. A recent article discussing the company reads, “The imminent clinical use of a novel, frozen formulation of Bria-IMT is another exciting development for BriaCell. The company’s frozen formulation allows for the storage of … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Working to Fill Vital Need for Effective, Lasting Breast Cancer Treatments”

Contact us: 212.418.1217